Taxslave70, it appears as though the CVR's are still in play.
Ani has been reluctant to release anything with respect to Libigel. In addition to discovering that Libigel reduces CV events by at least 70%, someone (most likely other that ANI) discovered that Libigel also reduces Breast Cancer. Neither discovery have ever been disclosed publicly outside of the patent applications. Why would a company, first BPAX and now ANIP, keep these price moving discoveries under wraps, unless they are bound by confidentiality agreements.
Since the breast cancer reduction benefit was not noticeable by September 2012, when BPAX announced they were completing the trial, it highly likely that the patients were monitored for the full 5 years as per FDA protocol. Thhis is where they probably discovered that Libigel also reduced breast cancer. If so, then the last patient follow up would have been August, 2016.
Between August 2016 and October 2016:
• Dentons on behalf of ANI has filed 3 new patent applications (all presently pending) claiming benefits of the three patent applications filed by Biosante in 2011.
• Dentons also allowed the Libigel trademark to expire without submitting a new name to replace it on behalf of ANI. And,
• Libigel which had been marketed as a licensing opportunity on the Deals.bio website, has since been removed. At no time did it ever advertise the cardiovascular or breast cancer event reduction
Since ANIP does not mention any R&D expenses related to Libigel in their filings zand there R&D expenses have been small and mostly tied up with the Corti drugs,it is unlikely that they have spent anywhere near the $2.5 million.
If Libigel is acquired, the acquiring company is still on the hook for the CVRs
Personally, I believe an announcement will be made before the patent application involving the Breast Cancer claims gets published, as the specifications document will most likely identify the existence of partner and more details of the analysis.
